drugset / Trial / NCT00464815

Non-Inferiority of Meningococcal Vaccine GSK134612 Versus Mencevax™ in 11-17 Year-Old Subjects

NCT00464815

Phase 3 Completed 1025 enrolled GlaxoSmithKline
RandomizedParallel-groupOpen-labelPrevention

Summary

The purpose of this study is to demonstrate, in 11-17 year old subjects, the non-inferiority of meningococcal vaccine GSK134612 compared to licensed meningococcal vaccine Mencevax™.

Timeline

Start
2007-05-02
Primary completion
2008-04-16
Completion
2008-09-10

Drugs

EvaluationDrugModalityDoseRoute
Subject GSK134612 Vaccine Intramuscular
Comparator Mencevax™ ACWY Vaccine Subcutaneous